Literature DB >> 16220555

Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.

Jacopo Peccatori1, Lisbeth Barkholt, Tanner Demirer, Maria Pia Sormani, Paolo Bruzzi, Fabio Ciceri, Alberto Zambelli, Gian Antonio Da Prada, Paolo Pedrazzoli, Salvatore Siena, Gero Massenkeil, Rodrigo Martino, Stig Lenhoff, Paolo Corradini, Giovanni Rosti, Olle Ringden, Marco Bregni, Dietger Niederwieser.   

Abstract

BACKGROUND: The objective of this study was to identify prognostic factors for predicting survival in patients with advanced renal cell carcinoma (RCC) who had undergone an allogeneic stem cell transplantation after failure on immunotherapy.
METHODS: The authors studied 70 patients with advanced RCC who underwent allogeneic transplantation with a fludarabine-based, reduced-intensity regimen. Ten parameters were analyzed at the time of transplantation for their power to predict survival. Clinical features were examined first univariately; then, variables that were correlated significantly with survival in the univariate analysis were included in a multivariate Cox regression model.
RESULTS: Factors that were found to be associated significantly with limited survival were performance status, the number of metastatic sites, the presence of mediastinal metastasis, hemoglobin level, C-reactive protein (CRP) level, lactate dehydrogenase (LDH) level, and neutrophil counts. All these variables were included in a multivariate Cox regression model, and three were retained in the final model. Patients were classified according to the score estimated by the final Cox model in two groups (above or below the median value): The median survival was 3.5 months for patients who had a poor prognosis patients versus 23 months for patients who had a good prognosis.
CONCLUSIONS: The current findings suggested that three easily available parameters (performance status, CRP level, and LDH level) could be used to stratify patients with advanced RCC who are candidates for allografting and to assist clinicians in decision-making and selection of an appropriate treatment program. Copyright 2005 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220555     DOI: 10.1002/cncr.21477

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.

Authors:  Brenda M Sandmaier; Stephen Mackinnon; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

Review 2.  Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Ying Wu; Xiaonan Fu; Xiaoli Zhu; Xuelian He; Chao Zou; Yijie Han; Mingchu Xu; Chengjin Huang; Xin Lu; Yulan Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

3.  Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma.

Authors:  R Crocchiolo; O Ringden; J-O Bay; D Blaise; B Omasic; B Mazzi; C Picard; S Trinca; L Barkholt; J Peccatori; S Gregori; G Amodio; K Fleischhauer; F Ciceri; M Bregni
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

Review 4.  Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.

Authors:  Scott S Tykodi; Brenda M Sandmaier; Edus H Warren; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2011-03-21       Impact factor: 4.388

Review 5.  Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

Authors:  Erden Atilla; Pinar Ataca Atilla; Taner Demirer
Journal:  Int J Hematol       Date:  2016-12-19       Impact factor: 2.490

Review 6.  A review of infectious complications after haploidentical hematopoietic stem cell transplantations.

Authors:  Erden Atilla; Pinar Ataca Atilla; Sinem Civriz Bozdağ; Taner Demirer
Journal:  Infection       Date:  2017-04-17       Impact factor: 3.553

Review 7.  Reporting methods in studies developing prognostic models in cancer: a review.

Authors:  Susan Mallett; Patrick Royston; Susan Dutton; Rachel Waters; Douglas G Altman
Journal:  BMC Med       Date:  2010-03-30       Impact factor: 8.775

Review 8.  Reporting performance of prognostic models in cancer: a review.

Authors:  Susan Mallett; Patrick Royston; Rachel Waters; Susan Dutton; Douglas G Altman
Journal:  BMC Med       Date:  2010-03-30       Impact factor: 8.775

Review 9.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17

Review 10.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.